Literature DB >> 8943505

Salpingectomy improves in-vitro fertilization outcome in patients with a hydrosalpinx: blind victimization of the fallopian tube?

P J Puttemans1, I A Brosens.   

Abstract

Entities:  

Mesh：

Year:  1996        PMID： 8943505     DOI： 10.1093/oxfordjournals.humrep.a019052

Source DB:  PubMed          Journal:  Hum Reprod        ISSN： 0268-1161            Impact factor:   6.918


× No keyword cloud information.
  7 in total

1.  Controlled ovarian hyperstimulation adversely affects implantation following in vitro fertilization-embryo transfer.

Authors:  J H Check; J K Choe; D Katsoff; D Summers-Chase; C Wilson
Journal:  J Assist Reprod Genet       Date:  1999-09       Impact factor: 3.412

Review 2.  Mild ovarian stimulation.

Authors:  Jerome H Check
Journal:  J Assist Reprod Genet       Date:  2007-12-04       Impact factor: 3.412

3.  Salpingectomy for repeated embryo nonimplantation after in vitro fertilization in patients with severe tubal factor infertility.

Authors:  H Dechaud; T Anahory; N Aligier; F Arnal; H Humeau; B Hedon
Journal:  J Assist Reprod Genet       Date:  2000-04       Impact factor: 3.412

Review 4.  Surgical treatment for tubal disease in women due to undergo in vitro fertilisation.

Authors:  Neil Johnson; Sabine van Voorst; Martin C Sowter; Annika Strandell; Ben Willem J Mol
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

5.  Hydrosalpinx functional surgery or salpingectomy? The importance of hydrosalpinx fluid in assisted reproductive technologies.

Authors:  Mandakini Parihar; Aparna Mirge; Reshma Hasabe
Journal:  J Gynecol Endosc Surg       Date:  2009-01

Review 6.  Is There Still a Place for Reconstructive Surgery in Distal Tubal Disease?

Authors:  Bogdan Obrzut; Marzanna Obrzut
Journal:  J Clin Med       Date:  2022-06-08       Impact factor: 4.964

7.  The fallopian tube microbiome: implications for reproductive health.

Authors:  Elise S Pelzer; Dana Willner; Melissa Buttini; Louise M Hafner; Christina Theodoropoulos; Flavia Huygens
Journal:  Oncotarget       Date:  2018-04-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.